<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7267115\results\search\testTrace\results.xml">
  <result pre="doi: 10.1111/apt.15779APT15779 : Review Article: Review Articles Review article: prevention," exact="diagnosis" post="and management of COVIDâ€�19 in the IBD patient ALâ€�ANI"/>
  <result pre="the COVIDâ€�19 pandemic, review unique concerns regarding IBD management and" exact="infection" post="risk during the pandemic and assess COVIDâ€�19 management options"/>
  <result pre="patients do not appear to be more susceptible to SARSâ€�CoVâ€�2" exact="infection" post="and there is no evidence of an association between"/>
  <result pre="possible highâ€�dose systemic corticosteroids should be avoided. Patients should exercise" exact="social distancing," post="optimise coâ€�morbidities and be up to date with influenza"/>
  <result pre="patient develops COVIDâ€�19, immune suppressing medications should be withheld until" exact="infection" post="resolution and if trial medications for COVIDâ€�19 are being"/>
  <result pre="page-count: word-count: Alâ€�AniAH, PrenticeRE, RentschCA, et al. Review article: prevention," exact="diagnosis" post="and management of COVIDâ€�19 in the IBD patient. Aliment"/>
  <result pre="be implemented to reduce these risks and issues surrounding the" exact="treatment" post="of COVIDâ€�19, including potential drug interactions and IBD medication"/>
  <result pre="SARSâ€�CoVâ€�2 patients.19, 22, 29 These characteristics may have implications regarding" exact="isolation" post="and decisionâ€�making for IBD patients who are infected with"/>
  <result pre="is a recent case report of a possible SARSâ€�CoVâ€�2 gastrointestinal" exact="infection" post="causing acute haemorrhagic colitis and signalling COVIDâ€�19 disease.31 It"/>
  <result pre="if an IBD patients presents with worsening gastrointestinal symptoms, COVIDâ€�19" exact="infection" post="should be considered as a differential. 3.3 Demographics The"/>
  <result pre="is male. Healthcare workers may be at increased risk of" exact="infection" post="secondary to close contact with infected patients and exposure"/>
  <result pre="children under the age of 18Â years have a low" exact="infection" post="rate (2.4%), with a large proportion being identified through"/>
  <result pre="infection rate (2.4%), with a large proportion being identified through" exact="contact tracing" post="in adults rather than through symptomatology.16 3.4 Disease course"/>
  <result pre="rate (2.4%), with a large proportion being identified through contact" exact="tracing" post="in adults rather than through symptomatology.16 3.4 Disease course"/>
  <result pre="has been documented highlighting the challenge in the identification and" exact="isolation" post="of individuals at an early stage of disease.35 In"/>
  <result pre="0.02])44 are significant nonpharmacological risk factors that are modifiable for" exact="infection" post="and therefore nutritional support and medical treatment aiming for"/>
  <result pre="are modifiable for infection and therefore nutritional support and medical" exact="treatment" post="aiming for disease control should be optimised.41, 42 Furthermore,"/>
  <result pre="bowel,48 there is also a theoretical increased risk of SARSâ€�CoVâ€�2" exact="infection" post="via the gut in IBD patients. Despite this, there"/>
  <result pre="patients. Despite this, there is no current evidence of increased" exact="infection" post="rates or worse disease severity of COVIDâ€�19 in IBD"/>
  <result pre="reported.50 This appears to be a notable underâ€�representation of COVIDâ€�19" exact="infection" post="in IBD patients compared to the prevalence of IBD"/>
  <result pre="underâ€�representation of COVIDâ€�19 infection in IBD patients compared to the" exact="prevalence" post="of IBD and COVIDâ€�19 separately in the community. As"/>
  <result pre="it is unclear if this is secondary to low COVIDâ€�19" exact="infection" post="rates or to significant underâ€�reporting of COVIDâ€�19 infection in"/>
  <result pre="low COVIDâ€�19 infection rates or to significant underâ€�reporting of COVIDâ€�19" exact="infection" post="in IBD patients. 3.6 Diagnosis A diagnosis of COVIDâ€�19"/>
  <result pre="underâ€�reporting of COVIDâ€�19 infection in IBD patients. 3.6 Diagnosis A" exact="diagnosis" post="of COVIDâ€�19 should be considered in patients who display"/>
  <result pre="presence of diarrhoea initially and these patients often experience delayed" exact="diagnosis" post="compared to those that present with respiratory symptoms.51 Biochemical"/>
  <result pre="COVIDâ€�19 will vary depending on the local guidelines, availability of" exact="testing" post="kits and regional transmission dynamics. In highâ€�risk settings where"/>
  <result pre="or unexplained fever. Diagnosis of COVIDâ€�19 is via nucleic acid" exact="testing" post="of nasopharyngeal and oropharyngeal swabs.52 Serology testing is currently"/>
  <result pre="via nucleic acid testing of nasopharyngeal and oropharyngeal swabs.52 Serology" exact="testing" post="is currently not widely available. It is important to"/>
  <result pre="It is important to ensure that routine local protocols for" exact="testing" post="in acute pneumonia/pneumonitis are also followed, such as bacterial"/>
  <result pre="cytokine storm resulting in ARDS. Table 2 IBD medications and" exact="infection" post="risk Â Risk of respiratory tract infections Risk of"/>
  <result pre="the 5â€�ASA medications are used as firstâ€�line induction and maintenance" exact="treatment" post="for UC. 5â€�ASAs have very mild immunosuppressive activity and"/>
  <result pre="of these medications being associated with an increased risk of" exact="infection" post="and studies of large cohorts evaluating the safety profile"/>
  <result pre="in contact with someone who has COVIDâ€�19 or develops COVIDâ€�19," exact="treatment" post="with 5â€�ASA should continue. 4.2 Corticosteroids Corticosteroids systemically reduce"/>
  <result pre="to viral suppression.54 Corticosteroids have therefore been trialled in the" exact="treatment" post="of coronavirusâ€™, including COVIDâ€�19.54, 55, 56 However corticosteroids in"/>
  <result pre="0.4, 95% CI 0.2â€�0.7; PÂ =Â 0.0005).55 In SARS, corticosteroid" exact="treatment" post="was of no clinical benefit in regard to infection"/>
  <result pre="corticosteroid treatment was of no clinical benefit in regard to" exact="infection" post="resolution but was associated with an increased risk of"/>
  <result pre="and avascular necrosis.60 Finally, in a systematic review on corticosteroid" exact="treatment" post="in influenza patients, corticosteroids were associated with an increased"/>
  <result pre="an increased risk of infection; however, it is unclear if" exact="treatment" post="with corticosteroids is associated with an increased risk of"/>
  <result pre="with corticosteroids is associated with an increased risk of COVIDâ€�19" exact="infection" post="or complications. Where possible, corticosteroid use should be avoided"/>
  <result pre="or combination therapy, with a view to maintaining remission in" exact="isolation" post="or enhancing the pharmacologic profile of the biologics. These"/>
  <result pre="inflammatory disease population, there was not an increased risk of" exact="infection" post="with methotrexate (1.03, 95% CI0.82â€�1.3).73 This applied similarly to"/>
  <result pre="increased risk of respiratory infections, and hence COVIDâ€�19, with vedolizumab" exact="treatment" post="as vedolizumab binds the Tâ€�cell integrin receptor Î±4Î²7, inhibiting"/>
  <result pre="deep remission and/or older, consider withholding/ceasing immunomodulator therapy to reduce" exact="infection" post="risk. If possible utilise therapeutic drug monitoring to guide"/>
  <result pre="(18.8%) and nasopharyngitis (14.6%) comparable to that of antiâ€�TNFs.90 Serious" exact="infection" post="was found to be increased with tofacitinib in the"/>
  <result pre="tofacitinib in the induction trials for UC, but similar across" exact="treatment" post="groups including placebo in the maintenance trial.91 Of 4789"/>
  <result pre="100 PY [95% CI 2.73, 3.49]), and the most common" exact="infection" post="was pneumonia.92 Higher doses of 10Â mg twice daily"/>
  <result pre="and diabetes were also independent factors associated with increased serious" exact="infection" post="risk.92, 93 Therefore, patients on tofacitinib should be maintained"/>
  <result pre="patient clears the infection. 4.6 Recommencement of medications following COVIDâ€�19" exact="infection" post="If a patient is exposed to or gets infected"/>
  <result pre="their IBD medication, recommencement of medication can occur once the" exact="infection" post="has been cleared. To clear a patient of COVIDâ€�19:"/>
  <result pre="has been cleared. To clear a patient of COVIDâ€�19: Where" exact="testing" post="is available: patients can be cleared of COVIDâ€�19 if"/>
  <result pre="hour intervals at least 8Â days after symptom onset.95 Where" exact="testing" post="capacity is limited: due to potential prolonged shedding, guidelines"/>
  <result pre="and mucosal secretory antibody formation, and is associated with increased" exact="infection" post="risk in IBD patients.96 Smoking has been associated with"/>
  <result pre="water for 20Â seconds or use an alcohol rub, practice" exact="social distancing" post="by working from home, standing 2Â m apart from"/>
  <result pre="and if patients require a procedure they should have prior" exact="screening" post="for COVIDâ€�19 if symptomatic. In addition, to limit pharmacy"/>
  <result pre="prior to determine their risk of COVIDâ€�19. This should include" exact="screening" post="for COVIDâ€�19 symptoms, confirming no direct contact with a"/>
  <result pre="be moved to a â€˜cleanâ€™ COVIDâ€�19 free area. In addition," exact="social distancing" post="between patients chairs should occur and a single nurse"/>
  <result pre="occur and a single nurse per patient arranged to prevent" exact="infection" post="spread. Finally, where possible, infliximab infusions should be converted"/>
  <result pre="develop COVIDâ€�19, there are no therapeutic options approved for the" exact="treatment" post="of coronaviruses. Management of COVIDâ€�19 predominantly focuses on supportive"/>
  <result pre="care systems worldwide has encouraged clinicians to examine all possible" exact="treatment" post="options. WHO has created a master protocol for a"/>
  <result pre="of the safety and efficacy of investigative therapies for the" exact="treatment" post="of COVIDâ€�19.101 There are many drug trials currently occurring."/>
  <result pre="days â†‘ myelosuppression risk. Recommend ceasing thiopurine in acute severe" exact="infection" post="â†‘ myelosuppression risk. Recommend ceasing methotrexate in acute severe"/>
  <result pre="infection â†‘ myelosuppression risk. Recommend ceasing methotrexate in acute severe" exact="infection" post="â†‘ risk of QTâ€�interval prolongation. consider baseline and follow"/>
  <result pre="GSâ€�441524 that incorporates into nascent viral RNA chains, inhibiting virus" exact="infection" post="in a human cell line (human liver cancer Huh"/>
  <result pre="significant improvement in time to discharge or clinical improvement. However," exact="treatment" post="was commenced late in the diseases course and only"/>
  <result pre="potential of QT prolongation. More evidence is required before this" exact="treatment" post="can be recommended. 6.4 Favipiravir (Tâ€�705) Favipiravir, a guanine"/>
  <result pre="122 (29%) involved the examination of Chinese medicines for the" exact="treatment" post="of COVIDâ€�19. As clinicians we need to be aware"/>
  <result pre="immunosuppression and this may lead to an increased risk of" exact="infection" post="with SARSâ€�CoVâ€�2 and complications arising from COVIDâ€�19. Despite this,"/>
  <result pre="COVIDâ€�19 compared to the general population. These guidelines summarise the" exact="treatment" post="approach to IBD patients in the current climate and"/>
  <result pre="develop COVIDâ€�19, immunosuppressive medications should be withheld where possible until" exact="infection" post="resolution and if a medication trial is being considered"/>
  <result pre="Gastroenterol. 2015;6:169â€&quot;174.28839807 5JeongDY, KimS, SonMJ, et al. Induction and maintenance" exact="treatment" post="of inflammatory bowel disease: a comprehensive review. Autoimmun Rev."/>
  <result pre="AbreuC, et al. Second European evidenceâ€�based consensus on the prevention," exact="diagnosis" post="and management of opportunistic infections in inflammatory bowel disease."/>
  <result pre="ZappettiD, et al. Incidence, significance, and persistence of human coronavirus" exact="infection" post="in hematopoietic stem cell transplant recipients. Bone Marrow Transplant."/>
  <result pre="Nature. 2020. 28RotheC, SchunkM, SothmannP, et al. Transmission of 2019â€�nCoV" exact="infection" post="from an asymptomatic contact in Germany. N Engl J"/>
  <result pre="Med. 2020;382:970â€&quot;971.32003551 29XiaoF, TangM, ZhengX, et al. Evidence for gastrointestinal" exact="infection" post="of SARSâ€�CoVâ€�2. Gastroenterology. 2020;158:1831â€&quot;1833.32142773 30PanL, MuM, YangP, et al."/>
  <result pre="2020;115:766â€&quot;773 (In Press).32287140 31CarvalhoA, AlqusairiR, AdamsA, et al. SARSâ€�CoVâ€�2 gastrointestinal" exact="infection" post="causing hemorrhagic colitis: implications for detection and transmission of"/>
  <result pre="et al. SARSâ€�CoVâ€�2 gastrointestinal infection causing hemorrhagic colitis: implications for" exact="detection" post="and transmission of COVIDâ€�19 disease. Am J Gastroenterol. 2020;In"/>
  <result pre="Pediatrics. 2020. 40HakkiM, RattrayRM, PressRD. The clinical impact of coronavirus" exact="infection" post="in patients with hematologic malignancies and hematopoietic stem cell"/>
  <result pre="GarciaN, PascualI, et al. Clinical assessment of risk factors for" exact="infection" post="in inflammatory bowel disease patients. Int J Colorectal Dis."/>
  <result pre="disease patients from the outbreak and rapid spread of COVIDâ€�19" exact="infection" post="in Wuhan, China. Lancet. 2020 (In Press). 50BrennerEJ, UngaroR,"/>
  <result pre="Medicines. Gut. 2002;51:536â€&quot;539.12235076 54StockmanLJ, BellamyR, GarnerP. SARS: systematic review of" exact="treatment" post="effects. PLoS Med. 2006;3:e343.16968120 55ArabiYM, MandourahY, Alâ€�HameedF, et al."/>
  <result pre="58LeeN, Allen ChanKC, HuiDS, et al. Effects of early corticosteroid" exact="treatment" post="on plasma SARSâ€�associated Coronavirus RNA concentrations in adult patients."/>
  <result pre="disease. Am J Gastroenterol. 2013;108:240â€&quot;248.23295276 63OrlickaK, BarnesE, CulverEL. Prevention of" exact="infection" post="caused by immunosuppressive drugs in gastroenterology. Ther Adv Chronic"/>
  <result pre="al. Oral prolonged release beclomethasone dipropionate and prednisone in the" exact="treatment" post="of active ulcerative colitis: results from a doubleâ€�blind, randomized,"/>
  <result pre="et al. Risk of serious and opportunistic infections associated with" exact="treatment" post="of inflammatory bowel diseases. Gastroenterology. 2018;155:337â€&quot;46. e10.29655835 71SeksikP, CosnesJ,"/>
  <result pre="coronavirus. Antiviral Res. 2015;115:9â€&quot;16.25542975 73IbrahimA, AhmedM, ConwayR, CareyJJ. Risk of" exact="infection" post="with methotrexate therapy in inflammatory diseases: a systematic review"/>
  <result pre="controlled trials. BMJ. 2015;350:h1269.25770113 75LichtensteinGR, FeaganBG, CohenRD, et al. Serious" exact="infection" post="and mortality in patients with Crohn's disease: more than"/>
  <result pre="Gastroenterol. 2012;107:1409â€&quot;1422.22890223 76ShahED, FaridaJP, SiegelCA, et al. Risk for overall" exact="infection" post="with antiâ€�TNF and antiâ€�integrin agents used in IBD: a"/>
  <result pre="Med. 2016;375:1946â€&quot;1960.27959607 81KalbRE, FiorentinoDF, LebwohlMG, et al. Risk of serious" exact="infection" post="with biologic and systemic treatment of psoriasis: results from"/>
  <result pre="et al. Risk of serious infection with biologic and systemic" exact="treatment" post="of psoriasis: results from the psoriasis longitudinal assessment and"/>
  <result pre="et al. IMâ€�UNITI: threeâ€�year efficacy, safety, and immunogenicity of ustekinumab" exact="treatment" post="of Crohn's disease. J Crohns Colitis. 2020;14:23â€&quot;32.31158271 83ByeWA, JairathV,"/>
  <result pre="JairathV, TravisSPL. Systematic review: the safety of vedolizumab for the" exact="treatment" post="of inflammatory bowel disease. Aliment Pharmacol Ther. 2017;46:3â€&quot;15.28449273 84MockoP,"/>
  <result pre="trial. Gut. 2012;61:229â€&quot;234.21948942 89WinthropKL, MelmedGY, VermeireS, et al. Herpes zoster" exact="infection" post="in patients with ulcerative colitis receiving tofacitinib. Inflamm Bowel"/>
  <result pre="efficacy of tofacitinib for up to 9.5 years in the" exact="treatment" post="of rheumatoid arthritis: final results of a global, openâ€�label,"/>
  <result pre="and Control . Technical Report: Guidance for discharge and ending" exact="isolation" post="in the context of widespread community transmission of COVIDâ€�19"/>
  <result pre="Emerg Infect Dis. 2020;26:976â€&quot;984.32027585 98AhmedF, ZviedriteN, UzicaninA. Effectiveness of workplace" exact="social distancing" post="measures in reducing influenza transmission: a systematic review. BMC"/>
  <result pre="of the safety and efficacy of investigational therapeutics for the" exact="treatment" post="of COVIDâ€�19 in hospitalized patients.2020. 102AgostiniML, AndresEL, SimsAC, et"/>
  <result pre="novel coronavirus (2019â€�nCoV) in vitro. Cell Res. 2020;30:269â€&quot;271.32020029 104LuH. Drug" exact="treatment" post="options for the 2019â€�new coronavirus (2019â€�nCoV). BioSci Trends. 2020."/>
  <result pre="105ChuCM, ChengVC, HungIF, et al. Role of lopinavir/ritonavir in the" exact="treatment" post="of SARS: initial virological and clinical findings. Thorax. 2004;59:252â€&quot;256.14985565"/>
  <result pre="al. Treatment with lopinavir/ritonavir or interferonâ€�beta1b improves outcome of MERSâ€�CoV" exact="infection" post="in a nonhuman primate model of common marmoset. J"/>
  <result pre="111GautretP, LagierJâ€�C, ParolaP, et al. Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVIDâ€�19: results of an openâ€�label nonâ€�randomized clinical trial."/>
  <result pre="al. Contact and selfâ€�contact patterns of healthcare workers: implications for" exact="infection" post="prevention and control. Clin Infect Dis. 2019;69(Supplement_3):S178â€&quot;S184.31517975 118KuenzigME, RezaieA,"/>
  <result pre="119RizzelloF, GionchettiP, D'ArienzoA, et al. Oral beclometasone dipropionate in the" exact="treatment" post="of active ulcerative colitis: a doubleâ€�blind placeboâ€�controlled study. Aliment"/>
  <result pre="TanakaY, MarietteX, et al. Longâ€�term safety of tofacitinib for the" exact="treatment" post="of rheumatoid arthritis up to 8.5 years: integrated analysis"/>
  <result pre="HommesDW, van BodegravenAA. Clinical pharmacokinetic and pharmacodynamic considerations in the" exact="treatment" post="of inflammatory bowel disease. Clin Pharmacokinet. 2018;57:1075â€&quot;1106.29512050 125GisbertJP, NinoP,"/>
  <result pre="131HemperlyA, VandeCN. Clinical pharmacokinetics and pharmacodynamics of infliximab in the" exact="treatment" post="of inflammatory bowel disease. Clin Pharmacokinet. 2018;57:929â€&quot;942.29330783 132TianH, CronsteinBN."/>
  <result pre="Understanding the mechanisms of action of methotrexate: implications for the" exact="treatment" post="of rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007;65:168â€&quot;173.17922664"/>
 </snippets>
</snippetsTree>
